Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung

Small cell lung cancer (SCLC) remains a deadly form of cancer, with a 5-year survival rate of less than 10 percent, necessitating novel therapies. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protein that is emerging as a therapeutic target and is co-expressed with BCL2 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Walter Z., Shilo, Konstantin, Amann, Joseph M., Shulman, Alyssa, Hojjat-Farsangi, Mohammad, Mellstedt, Håkan, Schultz, Johan, Croce, Carlo M., Carbone, David P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178315/
https://www.ncbi.nlm.nih.gov/pubmed/34088900
http://dx.doi.org/10.1038/s41419-021-03855-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178315/
https://www.ncbi.nlm.nih.gov/pubmed/34088900
http://dx.doi.org/10.1038/s41419-021-03855-w

Ejemplares similares